GlaxoSmithKline expects to take a £1.57bn ($2.41bn) charge to resolve several long-running legal battles, including a probe into a former plant and litigation related to Paxil and Avandia, two blockbuster drugs.
The pharmaceuticals group announced the charge yesterday, a day after advisers to US regulators eased the risk that diabetes drug Avandia would be withdrawn from the market.
The £1.57bn includes £500m that GSK has provisionally agreed to pay to settle an investigation by the US government into alleged manufacturing problems at GSK's former facility in Cidra, Puerto Rico.
您已閱讀34%（583字），剩餘66%（1149字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。